Close Menu

Phase II Trouble

Phase II clinical trials are in trouble, says Pharmalot's Ed Silverman. According to a new study in Nature Reviews Drug Discovery, success rates for Phase II trials fell from 28 percent in 2006 and 2007 to 18 percent in 2008 and 2009. "The implication is that the overall attrition of late-stage drug development seems to be unsustainably high," Silverman says.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.

Science reports that Science Foundation Ireland is seeking annual budget increases.

According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.

In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.